 Based on DSMB review, in Feb 2008 participants who started the study with high viral loads were told whether they were taking ABC3TC or TDFFTC and offered the option to continue or change their NRTI study drug component, after discussion with their doctor. For participants who started the study with lower screening viral loads, study treatment continued without change. 